Biocartis Group

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

B1333M105
SEDOL

BXC7WF8
CIK

N/A

biocartis.com
LEI:
FIGI: BBG008HBYKH9
BCART

Biocartis Group
GICS: - · Sector: - · Sub-Sector: -
NAME
Biocartis Group
ISIN
BE0974281132
TICKER
BCART
MIC
XBRU
REUTERS
BCART.BR
BLOOMBERG
BCART BB
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
Eight Short sale positions >= 0.50% are currently registered as reportable-relevant
Date Position Holder Position # Action
16.06.2023 Whitebox Advisors LLC 1,21% 132
31.12.2022 Citadel Europe LLP 1,00% 1.340
28.11.2022 Quartys Limited 1,13% 7
26.05.2021 Millennium International Management LP 0,70% 3
17.03.2020 Highbridge Capital Management LLC 0,57% 318
08.03.2020 Voleon Capital Management LP 0,59% 47
05.05.2019 Millennium Capital Partners LLP 0,55% 3
04.03.2018 Numeric Investors LLC 0,50% 54
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
Date Position Holder Position # Action
16.06.2023 Whitebox Advisors LLC 1,21% 132
31.12.2022 Citadel Europe LLP 1,00% 1.340
28.11.2022 Quartys Limited 1,13% 7
26.05.2021 Millennium International Management LP 0,70% 3
17.03.2020 Highbridge Capital Management LLC 0,57% 318
08.03.2020 Voleon Capital Management LP 0,59% 47
05.05.2019 Millennium Capital Partners LLP 0,55% 3
04.03.2018 Numeric Investors LLC 0,50% 54
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.